Unique combination of FibroMeter™ blood test with FibroScan® result for optimal liver fibrosis assessment

First integrated diagnostic score meeting requirements of international guidelines: combination of liver stiffness measurement (FibroScan®) and blood markers (FibroMeter™)

Best algorithm to identify and manage patient from early to advanced fibrosis: maximized & consistent AUROCs performance across fibrosis stages (F2, F3, F4)

Optimal solution to confirm fibrosis stage assessment without liver biopsy: improved balance of Positive Predictive Value and Negative Predictive Value

Liver stiffness

One SCORE, one CLASSIFICATION:
optimum performance and easy to read

AST
GGT
PLT
A2M
PI

FibroMeter VCTE™ is an in vitro diagnostic medical device as defined by Directive 98/79/EC. These scores, based on blood parameters, are useful tools for diagnosing and measuring the extent of liver fibrosis in patients with chronic liver disease of viral (including HIV co-infection), alcohol-related, or metabolic origin. Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. FibroScan® examinations must be performed only by an operator who is certified by the manufacturer or its approved local representative. You are expressly recommended to carefully read the guide and the instructions given in the User Manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. This marketing tool is not intended for circulation in the United States. FibroScan® and FibroMeter VCTE™ are registered trademarks of Echosens™. © Copyright Echosens – All rights reserved - FibroMeter VCTE™ leaflet EN 0319.
Unique combination of FibroMeter™ blood test with FibroScan® result for optimal liver fibrosis assessment

Maximized & consistent performance across fibrosis stages (F2, F3, F4)
Performances in NAFLD patients (N = 225)

Optimal balance of diagnostic PPV & NPV
FibroScan® alone (LSM) and FibroMeter VCTE (FibroScan® + FibroMeter™) negative and positive predictive value (N=215)

First-in-class clinical performance:
FibroMeter VCTE™ outperforms other fibrosis tests
Performances in NAFLD patients for advanced fibrosis F≥3 (N = 410)